Form 8-K - Current report:
SEC Accession No. 0001193125-24-157310
Filing Date
2024-06-07
Accepted
2024-06-07 16:02:01
Documents
14
Period of Report
2024-06-06
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d94044d8k.htm   iXBRL 8-K 29193
2 EX-99.1 d94044dex991.htm EX-99.1 12495
  Complete submission text file 0001193125-24-157310.txt   173920

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA bmea-20240606.xsd EX-101.SCH 2865
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE bmea-20240606_lab.xml EX-101.LAB 18737
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE bmea-20240606_pre.xml EX-101.PRE 11717
17 EXTRACTED XBRL INSTANCE DOCUMENT d94044d8k_htm.xml XML 3758
Mailing Address 900 MIDDLEFIELD ROAD 4TH FLOOR REDWOOD CITY CA 94063
Business Address 900 MIDDLEFIELD ROAD 4TH FLOOR REDWOOD CITY CA 94063 (650) 980-9099
Biomea Fusion, Inc. (Filer) CIK: 0001840439 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40335 | Film No.: 241029181
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)